Cingulate Research Development Over Time
| CING Stock | USD 4.36 0.16 3.81% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cingulate Performance and Cingulate Correlation. Cingulate |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (43.22) | Return On Assets (1.04) | Return On Equity (2.74) |
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Research Development Analysis
Compare Cingulate and related stocks such as SAB Biotherapeutics, Senti Biosciences, and Bellicum Pharmaceuticals Research Development Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SABSW | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 8 M | 27.9 M | 57.2 M | 36.4 M | 16.5 M | 32.1 M |
| SNTI | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 14.5 M | 16 M | 22 M | 34.1 M | 32.1 M | 26.1 M |
| AVTE | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 3.1 M | 7.9 M | 15 M | 38.6 M | 64.2 M | 67.4 M |
| ADAG | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 16.2 M | 16.2 M | 68.1 M | 81.3 M | 36.6 M | 43 M |
| ACRV | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 13.7 M | 23.9 M | 45.5 M | 23.4 M |
| RZLT | 3.5 K | 3.5 K | 3.5 K | 34.3 K | 4.7 M | 9.4 M | 12.1 M | 17.3 M | 19.1 M | 14.4 M | 15 M | 32.5 M | 43.8 M | 55.7 M | 58.5 M |
| ANTX | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 6 M | 16.9 M | 29.5 M | 54.9 M | 57.6 M |
| GNLX | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 6.2 M | 6.3 M | 9.1 M | 12.8 M | 9.2 M |
| DYAI | 3.6 M | 950 K | 822 K | 1 M | 2.2 M | 885.6 K | 885.6 K | 2.2 M | 3.3 M | 4 M | 3.9 M | 8.4 M | 4.5 M | 3.3 M | 3 M |
| MNPR | 101.5 K | 101.5 K | 101.5 K | 101.5 K | 101.5 K | 101.5 K | 280.4 K | 15.4 M | 1.8 M | 2 M | 4.1 M | 6.5 M | 7.6 M | 5.6 M | 5.3 M |
| IKT | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 3.6 M | 2.6 M | 893.8 K | 11.4 M | 12 M | 13.6 M | 8.1 M |
| PMVP | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | 20.8 M | 23.9 M | 36.5 M | 52 M | 55.9 M | 37.2 M |
| ANEB | 150 K | 150 K | 150 K | 150 K | 150 K | 150 K | 150 K | 150 K | 150 K | 150 K | 2.3 M | 3 M | 5.6 M | 3.5 M | 3.2 M |
Cingulate and related stocks such as SAB Biotherapeutics, Senti Biosciences, and Bellicum Pharmaceuticals Research Development description
My Equities
My Current Equities and Potential Positions
| Cingulate | CING |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Kansas; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.36
Check out Cingulate Performance and Cingulate Correlation. For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Cingulate technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.